These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36820745)

  • 21. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
    Kapouni N; Moustaki M; Douros K; Loukou I
    Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
    Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
    J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
    Keens T; Hoffman V; Topuria I; Elder K; Cerf S; Mulder K; Roberts J; Lysinger J; Del Carmen Reyes M; Berdella M; Cairns AM; Jain M; Ganapathy V; Lou Y; Morcos B; Wu C; Sass L;
    Heliyon; 2024 Apr; 10(7):e28508. PubMed ID: 38586424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
    Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
    J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
    He R; Lin F; Deng Z; Yu B
    SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
    J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
    Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
    Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
    Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
    JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
    Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
    J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
    Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
    Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and effectiveness of treatment with elexacaftor, tezacaftor and ivacaftor in adults with cystic fibrosis.
    Nieto Royo R; Durán Barata D; Barrios Barreto D; Briceño Franquiz W; Máiz Carro L
    Med Clin (Barc); 2023 Oct; 161(8):338-341. PubMed ID: 37474394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis.
    Spoletini G; Gillgrass L; Pollard K; Shaw N; Williams E; Etherington C; Clifton IJ; Peckham DG
    J Cyst Fibros; 2022 Nov; 21(6):1061-1065. PubMed ID: 35585012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.